Shopping Cart
Remove All
Your shopping cart is currently empty
Parsatuzumab
🥰Excellent
Catalog No. T76756Cas No. 1312797-14-0
Alias RO-5490248, RG 7414, MEGF-0444A, MEGF0444A, M0444A, Anti-EGFL7
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interaction between EGFL7 and endothelial cells, and has an inhibitory effect on endothelial growth factor (VEGF).Parsatuzumab has been used in combination with other compounds for a long time. Combined use to study rectal cancer
Parsatuzumab
🥰Excellent
Catalog No. T76756Alias RO-5490248, RG 7414, MEGF-0444A, MEGF0444A, M0444A, Anti-EGFL7Cas No. 1312797-14-0
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interaction between EGFL7 and endothelial cells, and has an inhibitory effect on endothelial growth factor (VEGF).Parsatuzumab has been used in combination with other compounds for a long time. Combined use to study rectal cancer
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $157 | In Stock | In Stock | |
| 5 mg | $413 | - | In Stock | |
| 10 mg | $662 | - | In Stock | |
| 25 mg | $987 | - | In Stock | |
| 50 mg | $1,370 | - | In Stock | |
| 100 mg | $1,850 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:> 95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interaction between EGFL7 and endothelial cells, and has an inhibitory effect on endothelial growth factor (VEGF).Parsatuzumab has been used in combination with other compounds for a long time. Combined use to study rectal cancer |
| In vitro | EGFL7, a vascular-restricted extracellular matrix protein, promotes endothelial cell adhesion and survival[2]. Parsatuzumab inhibits cell proliferation and induces apoptosis in patient-derived xenograft (PDX) cells after 48 hours[1]. |
| In vivo | In several xenograft and genetically engineered murine tumor models, Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy[1].In mouse models of mantle cell lymphoma (MCL), Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7, inhibits MCL cell growth, and prolongs survival[1]. |
| Synonyms | RO-5490248, RG 7414, MEGF-0444A, MEGF0444A, M0444A, Anti-EGFL7 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 148.22 kDa |
| Cas No. | 1312797-14-0 |
| Color | Transparent |
| Appearance | Liquid |
Storage & Solubility Information
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Parsatuzumab | purchase Parsatuzumab | Parsatuzumab cost | order Parsatuzumab | Parsatuzumab chemical structure | Parsatuzumab in vivo | Parsatuzumab in vitro | Parsatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.